These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3065642)

  • 1. Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate.
    Cassel WA; Murray DR
    Nat Immun Cell Growth Regul; 1988; 7(5-6):351-2. PubMed ID: 3065642
    [No Abstract]   [Full Text] [Related]  

  • 2. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.
    Cassel WA; Murray DR
    Med Oncol Tumor Pharmacother; 1992; 9(4):169-71. PubMed ID: 1342060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in disease-free survival of melanoma patients in conjunction with serologic response in a phase Ia/Ib Southeastern Cancer Study Group trial of vaccinia melanoma oncolysate.
    Wallack MK; Bash J; Bartolucci A
    Am Surg; 1989 Apr; 55(4):243-7. PubMed ID: 2650593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate.
    Cassel WA; Murray DR; Phillips HS
    Cancer; 1983 Sep; 52(5):856-60. PubMed ID: 6871827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
    Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
    Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H).
    Csatary LK; Moss RW; Beuth J; Töröcsik B; Szeberenyi J; Bakacs T
    Anticancer Res; 1999; 19(1B):635-8. PubMed ID: 10216468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO).
    Wallack MK; McNally K; Michaelides M; Bash J; Bartolucci A; Siegler H; Balch C; Wanebo H
    Am Surg; 1986 Mar; 52(3):148-51. PubMed ID: 3513682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vaccine therapy of malignant tumors].
    Csatáry L; Gergely P
    Orv Hetil; 1990 Nov; 131(47):2585-8. PubMed ID: 2247306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of therapeutic vaccines of the management of malignant melanoma.
    Dalgleish AG; Souberbielle BE
    Cancer Surv; 1996; 26():289-319. PubMed ID: 8783580
    [No Abstract]   [Full Text] [Related]  

  • 10. Viral oncolysate in the management of malignant melanoma. II. Clinical studies.
    Murray DR; Cassel WA; Torbin AH; Olkowski ZL; Moore ME
    Cancer; 1977 Aug; 40(2):680-6. PubMed ID: 196740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus therapy of human cancers.
    Sinkovics JG; Horvath JC
    Melanoma Res; 2003 Aug; 13(4):431-2. PubMed ID: 12883372
    [No Abstract]   [Full Text] [Related]  

  • 12. [New aspects of immunotherapy of malignant melanoma].
    Enk A
    Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newcastle disease.
    Kelly A
    Proc R Soc Med; 1969 Aug; 62(8):821-2. PubMed ID: 5817828
    [No Abstract]   [Full Text] [Related]  

  • 14. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
    Cassel WA; Murray DR; Torbin AH; Olkowski ZL; Moore ME
    Cancer; 1977 Aug; 40(2):672-9. PubMed ID: 196739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment.
    Wallack MK; Meyer M; Bourgoin A; Doré JF; Leftheriotis E; Carcagne J; Koprowski H
    J Biol Response Mod; 1983; 2(6):586-96. PubMed ID: 6663322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated veterinary virus vaccine for the treatment of cancer.
    Csatary LK; Eckhardt S; Bukosza I; Czegledi F; Fenyvesi C; Gergely P; Bodey B; Csatary CM
    Cancer Detect Prev; 1993; 17(6):619-27. PubMed ID: 8275514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergic effects of interferon and interferon inducer against ectromelia virus infection in mice.
    Imanishi J; Won SJ; Matsubara M; Nomura H; Kishida T
    Biken J; 1980 Jun; 23(2):77-81. PubMed ID: 6161603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Production and trials of inactivated vaccines in oil excipient against Newcastle disease in Ethiopia].
    Thiaucourt F
    Rev Elev Med Vet Pays Trop; 1988; 41(3):229-33. PubMed ID: 3201019
    [No Abstract]   [Full Text] [Related]  

  • 19. Protection of chickens afforded by commercial lentogenic vaccines against challenge exposure to velogenic Newcastle disease virus.
    Butterfield WK; Dardiri AH; Yedloutschnig RJ
    Avian Dis; 1973; 17(2):279-82. PubMed ID: 4712800
    [No Abstract]   [Full Text] [Related]  

  • 20. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.